世界の動物用医薬品市場(~2027):送達方法別、製品別、動物種類別、エンドユーザー別、地域別

【英語タイトル】Veterinary Medicine Market Research Report by Mode of Delivery, Product, Animal Type, End-user, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが出版した調査資料(MRC2305D149)・商品コード:MRC2305D149
・発行会社(調査会社):360iResearch
・発行日:2022年10月
・ページ数:227
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3日)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名利用、印刷可)USD4,949 ⇒換算¥732,452見積依頼/購入/質問フォーム
Enterprise License(企業利用、印刷可)USD9,949 ⇒換算¥1,472,452見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

360iResearch社は、2021年に261.9億ドルであった世界の動物用医薬品市場規模が、2022年に281.2億ドルに成長し、更に年平均7.52%拡大して2027年までに404.9億ドルに達すると予測しています。当市場調査レポートでは、動物用医薬品の世界市場を多角的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、送達方法別(経口薬、非経口薬)分析、製品別(生物製剤、薬用飼料添加物、医薬品)分析、動物種類別(伴侶動物、生産動物)分析、エンドユーザー別(ポイントオブケア検査/機関内検査、リファレンスラボラトリー、動物病院&クリニック)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの内容を掲載しています。また、当書内の企業情報には、Archer-Daniels-Midland Company、Biogenesis Bago SA、C. H. Boehringer Sohn AG & Co. KG、Ceva Sante Animale、Dechra Pharmaceuticals PLC、Elanco Animal Health Incorporated、Evonik Industries AG、Hester Biosciences Limited、Indian Immunologicals Ltdなどが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の動物用医薬品市場規模:送達方法別
- 経口薬の市場規模
- 非経口薬の市場規模
・世界の動物用医薬品市場規模:製品別
- 生物製剤の市場規模
- 薬用飼料添加物の市場規模
- 医薬品の市場規模
・世界の動物用医薬品市場規模:動物種類別
- 伴侶動物における市場規模
- 生産動物における市場規模
・世界の動物用医薬品市場規模:エンドユーザー別
- ポイントオブケア検査/機関内検査における市場規模
- リファレンスラボラトリーにおける市場規模
- 動物病院&クリニックにおける市場規模
・世界の動物用医薬品市場規模:地域別
- 南北アメリカの動物用医薬品市場規模
アメリカの動物用医薬品市場規模
カナダの動物用医薬品市場規模
ブラジルの動物用医薬品市場規模
...
- アジア太平洋の動物用医薬品市場規模
日本の動物用医薬品市場規模
中国の動物用医薬品市場規模
インドの動物用医薬品市場規模
韓国の動物用医薬品市場規模
台湾の動物用医薬品市場規模
...
- ヨーロッパ/中東/アフリカの動物用医薬品市場規模
イギリスの動物用医薬品市場規模
ドイツの動物用医薬品市場規模
フランスの動物用医薬品市場規模
ロシアの動物用医薬品市場規模
...
- その他地域の動物用医薬品市場規模
・競争状況
・企業情報

The Global Veterinary Medicine Market size was estimated at USD 26.19 billion in 2021 and expected to reach USD 28.12 billion in 2022, and is projected to grow at a CAGR 7.52% to reach USD 40.49 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Veterinary Medicine to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Mode of Delivery, the market was studied across Oral and Parenteral.

Based on Product, the market was studied across Biologics, Medicated Feed Additives, and Pharmaceuticals. The Biologics is further studied across DNA Vaccines, Inactivated Vaccines, Live attenuated vaccines, and Recombinant Vaccines. The Pharmaceuticals is further studied across Analgesics, Anti-infectives, Anti-inflammatory, and Parasiticides.

Based on Animal Type, the market was studied across Companion and Production. The Companion is further studied across Cats, Dogs, and Horses. The Production is further studied across Cattle, Fish, Poultry, Sheep & Goats, and Swine.

Based on End-user, the market was studied across Point-of-care Testing/In-House Testing, Reference Laboratories, and Veterinary Hospitals & Clinics.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Veterinary Medicine market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Veterinary Medicine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Veterinary Medicine Market, including Archer-Daniels-Midland Company, Biogenesis Bago SA, C. H. Boehringer Sohn AG & Co. KG, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Evonik Industries AG, Hester Biosciences Limited, Indian Immunologicals Ltd, Kindred Biosciences, Inc., Merck & Co. Inc., Neogen Corporation, Nutreco N.V., Phibro Animal Health Corporation, Vetoquinol S.A., Virbac SA, and Zoetis Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Veterinary Medicine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Veterinary Medicine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Veterinary Medicine Market?
4. What is the competitive strategic window for opportunities in the Global Veterinary Medicine Market?
5. What are the technology trends and regulatory frameworks in the Global Veterinary Medicine Market?
6. What is the market share of the leading vendors in the Global Veterinary Medicine Market?
7. What modes and strategic moves are considered suitable for entering the Global Veterinary Medicine Market?

❖ レポートの目次 ❖

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rapid growth in global livestock population due to rising demand for meat and dairy production
5.1.1.2. Rise in pet adoption rates
5.1.1.3. Increasing cases of zoonotic and chronic diseases
5.1.2. Restraints
5.1.2.1. High influx of counterfeit drugs
5.1.3. Opportunities
5.1.3.1. Rising R&D and procedural advancements in vet medicine
5.1.3.2. Rising spending on pet care in urban areas
5.1.4. Challenges
5.1.4.1. Short product exclusivity period
5.2. Cumulative Impact of COVID-19

6. Veterinary Medicine Market, by Mode of Delivery
6.1. Introduction
6.2. Oral
6.3. Parenteral

7. Veterinary Medicine Market, by Product
7.1. Introduction
7.2. Biologics
7.3.1. DNA Vaccines
7.3.2. Inactivated Vaccines
7.3.3. Live attenuated vaccines
7.3.4. Recombinant Vaccines
7.3. Medicated Feed Additives
7.4. Pharmaceuticals
7.5.1. Analgesics
7.5.2. Anti-infectives
7.5.3. Anti-inflammatory
7.5.4. Parasiticides

8. Veterinary Medicine Market, by Animal Type
8.1. Introduction
8.2. Companion
8.3.1. Cats
8.3.2. Dogs
8.3.3. Horses
8.3. Production
8.4.1. Cattle
8.4.2. Fish
8.4.3. Poultry
8.4.4. Sheep & Goats
8.4.5. Swine

9. Veterinary Medicine Market, by End-user
9.1. Introduction
9.2. Point-of-care Testing/In-House Testing
9.3. Reference Laboratories
9.4. Veterinary Hospitals & Clinics

10. Americas Veterinary Medicine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Veterinary Medicine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Veterinary Medicine Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Archer-Daniels-Midland Company
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Biogenesis Bago SA
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. C. H. Boehringer Sohn AG & Co. KG
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Ceva Sante Animale
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Dechra Pharmaceuticals PLC
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Elanco Animal Health Incorporated
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Evonik Industries AG
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Hester Biosciences Limited
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Indian Immunologicals Ltd
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Kindred Biosciences, Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Merck & Co. Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Neogen Corporation
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Nutreco N.V.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Phibro Animal Health Corporation
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Vetoquinol S.A.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Virbac SA
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Zoetis Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing



★調査レポート[世界の動物用医薬品市場(~2027):送達方法別、製品別、動物種類別、エンドユーザー別、地域別] (コード:MRC2305D149)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の動物用医薬品市場(~2027):送達方法別、製品別、動物種類別、エンドユーザー別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆